Status:

COMPLETED

Intranasal Fentanyl in Preterm Infants Undergoing Peripherally Inserted Central Catheter Placement

Lead Sponsor:

Mount Sinai Hospital, Canada

Conditions:

Procedural Pain

Eligibility:

All Genders

Up to 1 years

Phase:

PHASE3

Brief Summary

The purpose of this feasibility clinical trial is to explore the role of intranasal fentanyl for pain associated with PICC placement in preterm infants. The primary goals are identifying whether enoug...

Detailed Description

Infants admitted to the neonatal intensive care unit (NICU) are subjected to multiple painful procedures as part of clinical care. It is established that early and repeated exposure to pain is associa...

Eligibility Criteria

Inclusion

  • Infants with a gestational age at birth \< 32 weeks or birth weight \< 1.5 kg
  • Infants considered medically appropriate for the study by the most responsible physician

Exclusion

  • Infants with choanal atresia, nasal mucosal erosion, or epistaxis
  • Infants with facial anomalies
  • Infants diagnosed with genetic conditions known to affect neurological development or severe (grade ≥ III) intraventricular hemorrhage
  • Infants receiving continuous intravenous infusions or scheduled enteral doses of opioids or sedatives within 12 hours of PICC placement
  • Infants with cardiopulmonary instability managed with inotropes, vasopressors, phosphodiesterase enzyme inhibitors, or neuromuscular blocking agents at the time of PICC placement
  • Infants prescribed strong CYP3A4 inhibitors (clarithromycin, itraconazole, ketoconazole, posaconazole, ritonavir, voriconazole) at the time of PICC placement
  • Infants diagnosed with bronchopulmonary dysplasia (need for supplemental oxygen or need for ventilatory support at 36 weeks corrected gestational age)
  • Infants with a previous documented adverse reaction to any formulation of fentanyl
  • Each eligible infant will be enrolled for one PICC placement only during the study period

Key Trial Info

Start Date :

August 9 2024

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 9 2025

Estimated Enrollment :

8 Patients enrolled

Trial Details

Trial ID

NCT06590870

Start Date

August 9 2024

End Date

February 9 2025

Last Update

February 20 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Mount Sinai Hospital

Toronto, Ontario, Canada, M5G 1X5